Morgan Stanley analyst Tejas Savant maintained a Buy rating on 10x Genomics (TXG – Research Report) today and set a price target of $26.00. The ...

Full Year 2024 Results Key Financial Results Revenue: US$610.8m (down 1.3% from FY ...

Barclays lowered the firm’s price target on 10x Genomics (TXG) to $15 from $18 and keeps an Overweight rating on the shares.Maximize Your ...

National Bank Financial boosted their FY2025 earnings per share (EPS) estimates for Torex Gold Resources in a report released ...

Fintel reports that on February 13, 2025, Leerink Partners downgraded their outlook for 10x Genomics (NasdaqGS:TXG) from ...

Moment President Donald Trump stunningly admits he can't 'understand a word' from foreign reporter drawing laughter during ...